Telix Pharmaceuticals (TLX) Stock Price, News & Analysis

Company Overview

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its products portfolio include Illuccix for the treatment of prostate cancer;, TLX591, a radio antibody-drug conjugate, which is in phase 3 clinical trial for the treatment of prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 746,789 shs
• Average Volume: N/A
• Market Capitalization: A$9.14 billion
• P/E Ratio: 290.42
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TLX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Telix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Telix Pharmaceuticals investors own include bluebird bio (BLUE), Atara Biotherapeutics (ATRA), Esperion Therapeutics (ESPR), Forte Biosciences (FBRX), Faraday Future Intelligent Electric (FFIE), Abbott Laboratories (ABT) and ADMA Biologics (ADMA).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:TLX
• CIK: N/A
• Web: www.telixpharma.com
• Phone: 61 4 4914 8448
• Fax: N/A
• Employees: 234
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A$0.15
• Trailing P/E Ratio: 290.42
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: A$49.19 million
• Net Margins: 6.63%
• Pretax Margin: N/A
• Return on Equity: 11.29%
• Return on Assets: 7.97%

Debt

• Debt-to-Equity Ratio: 5.48
• Current Ratio: 0.99
• Quick Ratio: 3.00

Sales & Book Value

• Annual Sales: A$645.68 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 8.35
• Book Value: A$1.21 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 334,680,000
• Free Float: N/A
• Market Cap: A$9.14 billion
• Optionable: Not Optionable
• Beta: 2.40